Replies to post #399025 on Amarin Corp Plc (AMRN)

[rosemountbomber]

I have to think, like you, if they found no appreciable difference - or at least some difference that could be made hay with, that it would be prudent to not say anything.

I can’t remember Pfizer saying that they tested generic atorvastatin and saying it is identical to Lipitor.

[ziploc_1]

The primary disadvantage with gV would be the oxidization of EPA in its inferior gelatin capsule...as compared with the oxidization of EPA in Vascepa....It would have made sense for Amarin to store gV on its shelves for x number of years and then to do tests to compare the oxidization of the EPA in gV compared to that of Vascepa.

The bad odor and bad taste of gV, alone, might not be enough for the FDA to take action.

[couldbebetter]

JRoon71, Amarin's great and illustrious management team did nothing
to differentiate Vascepa against Lovaza (branded & generic) which are
not even Cardiovascular drugs. So why would take any initiative now?
Simply put, I don't believe that AMRN management cares.

Face it, this management team has fumbled the ball too many times.
I thought KM was supposed to be the expert on getting reimbursements
in Europe, yet the most important country for Europe blindsided "the expert."
I used to believe that AMRN would have been acquired long ago for
the potential value of Europe. That a BP would want to handle the
reimbursement negotiations with their own skilled professionals.
The AMRN team screwed up the US, and may do the same with Europe.
China seems messed up as well. Where does it end with these guys?